SEC filings and other documents

Talicia® leads a late-stage pipeline with strong efficacy, broad coverage, and robust IP protection.

Talicia dominates as a first-line H. pylori therapy, driving growth and pipeline advancement.

Talicia leads H. pylori therapy, supported by strong financials and a diversified late-stage pipeline.

Talicia dominates H. pylori therapy as a robust pipeline targets GI, infectious, and cancer markets.

Strong U.S. growth, leading H. pylori therapy, and robust late-stage pipeline drive momentum.

Strategic partnerships and licensing drove improved equity and R&D progress despite operating losses.

Revenue up 59% and gross profit doubled, but going concern risk persists amid funding shortfall.

Late-stage pipeline and leading H. pylori therapy drive growth and market differentiation.

TaliciaⓇ leads H. pylori therapy as RedHill advances a de-risked, late-stage pipeline in key markets.

Revenue up 23%, cash burn down 74%, and R&D pipeline advanced with new global deals.

Net loss narrowed on an adjusted basis as cost cuts and pipeline progress offset lower revenues.